Drug Information

Drug General Information
Drug ID
D08PYO
Former ID
DNCL002533
Drug Name
KW-2478
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [522945]
Company
Kyowa Hakko Kirin
Structure
Download
2D MOL

3D MOL
Formula
C30H42N2O9
Canonical SMILES
CCC1=C(C=C(C(=C1CC(=O)N(CCOC)CCOC)C(=O)C2=CC(=C(C=C2)OC<br />CN3CCOCC3)OC)O)O
InChI
1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3
InChIKey
VFUXSYAXEKYYMB-UHFFFAOYSA-N
PubChem Compound ID
23116322
PubChem Substance ID
41614662, 55875241, 57289152, 136349552, 136367683, 136367903, 136946660, 144116114, 162011671, 162038049, 163642659, 164193954, 165246677, 172821442, 174007110, 174530869, 185972501, 198990894, 223401693, 223705138, 224076259, 225362716, 228931489, 244367096, 252215658, 252472232
Target and Pathway
Target(s) Heat shock protein HSP90 Target Info Modulator [531977]
References
Ref 522945ClinicalTrials.gov (NCT01063907) A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 531977Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.